Weight Loss Significantly Improves Liver Health in Obese Patients with MASLD

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), formerly known as NAFLD, is a growing global health concern, often progressing to more severe forms like cirrhosis and liver failure. It is strongly linked to obesity and metabolic syndrome, affecting a substantial portion of the population. Despite its prevalence and potential severity, the precise impact of various weight loss interventions on histological MASLD improvement across different clinical trial settings remains unclear, necessitating a comprehensive synthesis of existing evidence.

The analysis revealed a strong, dose-dependent relationship between weight loss and MASLD histological improvement. Patients achieving ≥5% weight loss showed a 30% greater likelihood of MASLD resolution compared to controls (p<0.05). This benefit escalated with more substantial weight reduction. > Achieving ≥10% total body weight loss was associated with a 2.5-fold increase in MASLD resolution and a 43% reduction in fibrosis progression (p<0.001). Specific interventions like GLP-1 agonists leading to 10-15% weight loss demonstrated comparable histological benefits to bariatric surgery, which typically achieves 20-30% weight loss. Even modest weight loss of 3-5% significantly improved steatosis by ~20%.